Abstract
Background Breast milk is considered to be the best substance for neonatal nutrition. It is not well known whether diabetes increases the expression of toxic heavy metals in the breast milk of postpartum mothers. This study compared the concentration of toxic heavy metals in breast milk between diabetic and non-diabetic postpartum mothers in Yenagoa.
Material and methods A cross-sectional design was utilized on a purposive sample of 144 consenting postpartum mothers (72 diabetic and 72 non-diabetic mothers) from one tertiary, one secondary, and one primary medical centre. Breast milk samples were collected at 5-6 weeks postpartum between 1st November 2020 and 30th April 2021. A spectrophotometer was used to analyze the breast milk samples. A pro forma was used for data extraction and data were analyzed at a 5% significance level.
Result The Diabetes group had levels of Arsenic (63.9%), Lead (95.8%), Mercury (68.1%), and Cadmium (84.7%) above the WHO permissible limits. The mean concentrations were 0.6 ng/ml (Arsenic), 13.2ng/ml (Lead), 2.9ng/ml (Mercury), and 3.3ng/ml (Cadmium). The non-diabetic mothers also had high levels of Arsenic (62.5%), Lead (95.8%), Mercury (72.2%), and Cadmium (86.1%); and the mean concentrations were 0.6ng/ml (Arsenic), 12.2 ng/ml (Lead), 3.0ng/ml (Mercury), and 3.2ng/ml (Cadmium). There was no significant difference in the concentration of toxic heavy metals in breast milk between the diabetic and non-diabetic postpartum mothers (p = > 0.585).
Conclusions Diabetes did not seem to increase the concentration of toxic heavy metals expressed in breast milk. More rigorous studies are needed to confirm these findings.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The authors received no specific funding for this work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Not Applicable
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
University of Port Harcourt Institutional Review Board (Approval ID: UPH/CEREMAD/REC/MM75/050)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Not Applicable
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Not Applicable
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Not Applicable
Footnotes
Funding information This study was not supported by any funding.
Conflict of interest statement The authors report no conflicts of interests.
Ethical approval This study was approved by the University of Port Harcourt Institutional Review Board (Approval ID: UPH/CEREMAD/REC/MM75/050)
Data Availability
All relevant data are within the manuscript and its Supporting Information files.
